focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInsig Ai Plc Regulatory News (INSG)

Share Price Information for Insig Ai Plc (INSG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.25
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.50 (12.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 13.25
INSG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Revision of Convertible Loan Facility Agreements

22 Dec 2022 07:00

RNS Number : 5449K
Insig AI Plc
22 December 2022
 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. It forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

22 December 2022 

Insig AI plc

("Insig AI" or the "Company")

Revision of Convertible Loan Facility Agreements

Insig AI plc (AIM: INSG), the data science and machine learning group, is pleased to announce the Company has agreed revised terms for the convertible loan note agreements with Richard Bernstein as announced on 3 May 2022 and David Kyte as announced on 16 June 2022 for £1m and £0.5m respectively. The Company and loan note holders have agreed to the following term revisions:

Richard Bernstein:

· interest owed on the first convertible loan facility to be rolled up into the loan expiring on 31 December 2023;

· interest of 8 per cent. per annum, (previously 5 per cent. per annum), which reflects the 2.25 per cent increase in UK base rates since May 2022 and the deterioration in debt capital markets and funding environment; and

· a conversion price of 20p, which represents a 25 per cent. premium to the closing share price on 21 December 2022 of 16p ("Current Share Price"), and the issuance of 1,666,667 warrants expiring on 31 December 2025 exercisable at a price of 30p, which represents an 87.5 per cent. premium to the Current Share Price.

David Kyte:

· interest owed on the first convertible loan facility to be rolled up into the loan expiring on 31 December 2023;

· interest of 8 per cent. per annum, (previously 5 per cent. per annum), which reflects the 2.25 per cent increase in UK base rates since May 2022 and the deterioration in debt capital markets and funding environment; and

· a conversion price of 18p, which represents a 12.5 per cent. premium to the Current Share Price, and the issuance of 1,388,889 warrants expiring on 31 December 2025 exercisable at a price of 25p, which represents a 56.25 per cent premium to the Current Share Price.

 

Richard Bernstein is a director of the Company. Accordingly, the revised terms of the convertible loan issued to him, is deemed to be a related party transaction pursuant to AIM Rule 13. The directors of the Company (excluding Richard Bernstein), having consulted with Zeus Capital Limited, the Company's nominated adviser, consider that the revised terms of his convertible loan are fair and reasonable insofar as the Company's shareholders are concerned.

For further information, please visit www.insg.ai or contact:  

Insig AI plc

Colm McVeigh (CEO)

colm.mcveigh@insg.ai

 

Zeus Capital Limited (Nominated Adviser & Broker)

David Foreman / James Hornigold / Danny Philips

 

+44 (0) 20 3829 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCTBBTTMTITTTT
12
Date   Source Headline
9th Sep 20227:00 amRNSFinal Results, Posting of Report and Notice of GM
8th Sep 20227:00 amRNSNotice of AGM
30th Aug 20227:00 amRNSConvertible Loan Facility Agreement and Drawdown
2nd Aug 20227:00 amRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSDirector/PDMR Shareholding
26th Jul 20227:00 amRNSConvertible Loan Facility Agreement drawdown
19th Jul 20227:00 amRNSDirectors' Disclosure
6th Jul 20227:00 amRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSDirector/PDMR Shareholding
17th Jun 202210:30 amRNSConvertible loan agreement and drawdown
31st May 20227:00 amRNSData partnership and research agreement
5th May 20227:00 amRNSData share partnership agreement with Snowflake
4th May 20227:00 amRNSConvertible Loan Facility Agreement and drawdown
28th Apr 20227:00 amRNSUpdate on agreement with CarVal Investors, L.P
26th Apr 20227:00 amRNSDirector/PDMR Shareholding
25th Apr 20227:00 amRNSContract win, trading update and Board changes
11th Apr 20227:00 amRNSDirectorate Change
24th Mar 20227:00 amRNSDirector/PDMR Shareholding
22nd Mar 20227:00 amRNSDirector/PDMR Shareholding
21st Mar 20227:00 amRNSTrading and operations update
25th Feb 20227:00 amRNSFurther agreement with CarVal Investors, L.P.
7th Feb 20227:00 amRNSInsig AI selected for PwC Scale FinTech programme
14th Jan 20227:00 amRNSDirector/PDMR Shareholding
6th Jan 20221:41 pmRNSDirector/PDMR Shareholding
30th Dec 20217:00 amRNSDirectorate change
23rd Dec 202112:55 pmRNSDirector/PDMR Shareholding
23rd Dec 20218:42 amRNSDirector/PDMR Shareholding
22nd Dec 20217:00 amRNSInterim Results
13th Dec 20217:00 amRNSContract win
10th Dec 20217:00 amRNSColm McVeigh appointment to the Board
19th Nov 202111:36 amRNSDirector/PDMR Shareholding
19th Nov 20217:00 amRNSDirector/PDMR Shareholding
18th Nov 20217:00 amRNSAcquisition of FDB Systems Limited
15th Nov 20217:00 amRNSProof of concept signed with asset manager
10th Nov 20217:00 amRNSESG scoring solution delivered to CarVal Investors
10th Nov 20217:00 amRNSColm McVeigh appointed as Chief Commercial Officer
4th Nov 20217:00 amRNSInvestor Presentation
1st Nov 20217:00 amRNSInsig AI Becomes a Sponsor of the UK's APPG on ESG
4th Oct 20217:00 amRNSRelease of Insig Portfolio 2.0
30th Sep 202111:10 amRNSResult of AGM
15th Sep 20217:00 amRNSLaunch of Insig ESG
17th Aug 20217:00 amRNSCarVal HY and IG product lines partnership
13th Aug 20217:30 amRNSDirectorate changes
23rd Jul 20217:00 amRNSInsig to support CarVal Clean CLO Product Line
20th Jul 20218:04 amRNSLicense win and ESG product developments
20th Jul 20217:00 amRNSLicense win and ESG product developments
18th May 20213:43 pmRNSHolding(s) in Company
10th May 20216:04 pmRNSHolding(s) in Company
10th May 20215:59 pmRNSHolding(s) in Company
10th May 20217:00 amRNSAdmission to Aim and First Day of Dealings
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.